Integrative in silico analysis suggests miR-152-3p as a potential regulator of DNMT1 in breast cancer, with implications for triple-negative breast cancer

Asuman Özgöz

doi:10.66235/kumj.1888856

Integrative in silico analysis suggests miR-152-3p as a potential regulator of DNMT1 in breast cancer, with implications for triple-negative breast cancer

Abstract

Aims: Epigenetic dysregulation plays a critical role in cancer initiation, progression, and therapeutic resistance. Among epigenetic mechanisms, DNA methylation—primarily maintained by DNA methyltransferase 1 (DNMT1)—is frequently altered in cancer, including triple-negative breast cancer (TNBC). This study aimed to systematically identify DNMT1-targeting microRNAs (miRNAs) and evaluate their potential regulatory roles using an integrative in silico approach.

Methods: DNMT1-targeting miRNAs were identified using TargetScan, DIANA-microT, and miRDB. Candidate miRNAs were further evaluated through an integrative multi-step analysis, including transcription factor and Gene Ontology (GO) enrichment analyses performed using the Enrichr platform, expression profiling and survival analysis using UALCAN, DNMT1 expression analysis across breast cancer subtypes using GEPIA2, and co-expression analysis using the ENCORI (starBase) platform.

Results: Four candidate miRNAs were identified as potential regulators of DNMT1. Expression and survival analyses indicated that hsa-miR-148b-3p is significantly upregulated in breast cancer (p = 1.62 × 10⁻¹²) and associated with poorer survival (p = 0.04), whereas hsa-miR-152-3p showed no significant association with expression or survival (p > 0.05). DNMT1 expression was consistently elevated across breast cancer subtypes, including basal-like tumors. Co-expression analysis revealed that only hsa-miR-152-3p demonstrated a statistically significant inverse correlation with DNMT1 expression (r = −0.159, p = 1.51 × 10⁻⁷), suggesting a potential post-transcriptional regulatory relationship. Functional enrichment analyses indicated that DNMT1-associated miRNAs are involved in transcriptional regulation, intracellular signaling pathways—including PI3K/AKT, Wnt, and TGF-β—and epithelial–mesenchymal transition (EMT)-related processes.

Conclusion: This integrative analysis suggests that DNMT1 regulation in breast cancer is selectively associated with specific miRNAs rather than broadly mediated by multiple candidates. Among the evaluated miRNAs, miR-152-3p emerged as the most consistent potential regulator of DNMT1, while miR-148b-3p appeared more closely associated with clinical outcomes. These findings highlight the potential relevance of the DNMT1–miRNA regulatory axis and provide a focused bioinformatic framework for future experimental studies investigating DNMT1–miRNA interactions, particularly in TNBC.

Keywords

References

Miranda Furtado CL, Dos Santos Luciano MC, Silva Santos RD, Furtado GP, Moraes MO, Pessoa C. Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics. 2019;14(12):1164-1176. doi:10.1080/15592294.2019.1640546
Pathak A, Tomar S, Pathak S. Epigenetics and Cancer: A Comprehensive Review. Asian Pac J Cancer Biol. 2023;8(1):75-89. https://doi.org/10.31557/apjcb.2023.8.1.75-89
Cheng Y, He C, Wang M, et al. Targeting epigenetic regulators for cancer therapy: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2019;4:62. doi:10.1038/s41392-019-0095-0
Liu Y, Sun Y, Yang J, et al. DNMT1-targeting remodeling global DNA hypomethylation for enhanced tumor suppression and circumvented toxicity in oral squamous cell carcinoma. Mol Cancer. 2024;23(1):104. doi:10.1186/s12943-024-01993-1
Wong KK. DNMT1: A key drug target in triple-negative breast cancer. Semin Cancer Biol. 2021;72:198-213. doi:10.1016/j.semcancer.2020.05.010
Yu J, Qin B, Moyer AM, et al. DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest. 2018;128(6):2376-2388. doi:10.1172/JCI97924
Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci U S A. 2007;104(40):15805–15810. doi:10.1073/pnas.0707628104
Jafarzadeh S, Jafarzadeh A, Zandvakili R, et al. Regulation and function of microRNA-152 in various types of cancers: its upstream regulators and downstream targets. Clin Exp Med. 2025;25(1):244. doi:10.1007/s10238-025-01775-z

Marques JHM, Mota AL, Oliveira JG, et al. Melatonin restrains angiogenic factors in triple-negative breast cancer by targeting miR-152-3p: in vivo and in vitro studies. Life Sci. 2018;208:131–138. doi:10.1016/j.lfs.2018.07.012
Dong C, Sun Y, Xu X, et al. c-Myc knockdown restores tamoxifen sensitivity in triple-negative breast cancer by reactivating the expression of ERα: the central role of miR-152 and miR-148a. Breast Cancer. 2025;32(3):529–542. doi:10.1007/s12282-025-01683-w
Raina N, Rani R, Kanojia M, et al. Nanotechnology-Driven Treatment Strategies for Breast Cancer: Recent Advances and Innovations. Oncol Res. 2025;33(10):2787-2831. doi:10.32604/or.2025.066624
Mirfattah B, Herring J, Tang H, Zhang K. Probes and Targets of DNA Methylation and Demethylation in Drug Development. Curr Top Med Chem. 2017;17(15):1727-1740. doi:10.2174/1568026617666161116143828
Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15-20. doi:10.1016/j.cell.2004.12.035
Paraskevopoulou MD, Georgakilas G, Kostoulas N, et al. DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 2013;41(Web Server issue):W169-W173. doi:10.1093/nar/gkt393
Liu W, Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 2019;20(1):18. doi:10.1186/s13059-019-1629-z
Gene Ontology Consortium, Aleksander SA, Balhoff J, et al. The Gene Ontology knowledgebase in 2023. Genetics. 2023;224(1):iyad031. doi:10.1093/genetics/iyad031
Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649–658. doi:10.1016/j.neo.2017.05.002
Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. 2019;47(W1):W556–W560. doi:10.1093/nar/gkz430
Li JH, Liu S, Zhou H, et al. starBase v2.0: decoding miRNA–ceRNA, miRNA–ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(D1):D92–D97. doi:10.1093/nar/gkt1248
Hao C, Sheng Z, Wang W, et al. Tumor-derived exosomal miR-148b-3p mediates M2 macrophage polarization via TSC2/mTORC1 to promote breast cancer migration and invasion. Thorac Cancer. 2023;14(16):1477-1491. doi:10.1111/1759-7714.14891
Mitri ZI, Abuhadra N, Goodyear SM, et al. Impact of TP53 mutations in Triple Negative Breast Cancer. NPJ Precis Oncol. 2022;6(1):64. doi:10.1038/s41698-022-00303-6
Tang M, O'Grady S, Crown J, Duffy MJ. MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975. Breast Cancer Res Treat. 2022;195(2):105-115. doi:10.1007/s10549-022-06673-6
Zhao Z, Han X, Nie C, et al. Circ_0008784 activates Wnt/β-catenin pathway to affect the proliferation and apoptosis of triple-negative breast cancer cells. Pathol Res Pract. 2023;241:154185. doi:10.1016/j.prp.2022.154185
Vishnubalaji R, Alajez NM. Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling. Sci Rep. 2021;11(1):15410. doi:10.1038/s41598-021-94514-9
Chien YC, Liu LC, Ye HY, et al. EZH2 promotes migration and invasion of triple-negative breast cancer cells via regulating TIMP2-MMP-2/-9 pathway. Am J Cancer Res. 2018;8(3):422-434
Ring A, Kaur P, Lang JE. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer. BMC Cancer. 2020;20(1):1076. doi:10.1186/s12885-020-07573-y
Kim J, Jang G, Sim SH, et al. SMARCA4 depletion induces cisplatin resistance by activating YAP1-mediated epithelial-to-mesenchymal transition in triple-negative breast cancer. Cancers (Basel). 2021;13(21):5474. doi:10.3390/cancers13215474
Damaskos C, Psilopatis I, Garmpi A, et al. Evaluation of the histone deacetylase 2 (HDAC-2) expression in human breast cancer. Cancers (Basel). 2024;16(1):209. doi:10.3390/cancers16010209
Xu X, Zhang L, He X, et al. TGF-β plays a vital role in triple-negative breast cancer (TNBC) drug resistance through regulating stemness, EMT and apoptosis. Biochem Biophys Res Commun. 2018;502(1):160-165. doi:10.1016/j.bbrc.2018.05.139
Mei C, Liu Y, Liu Z, et al. Dysregulated signaling pathways in canine mammary tumor and human triple negative breast cancer: advances and potential therapeutic targets. Int J Mol Sci. 2024;26(1):145. doi:10.3390/ijms26010145

Details

Primary Language

English

Subjects

Medical Genetics (Excl. Cancer Genetics)

Journal Section

Research Article

Authors

Asuman Özgöz ^*
0000-0003-4018-5807
Türkiye

Publication Date

June 16, 2026

Submission Date

February 15, 2026

Acceptance Date

June 3, 2026

Published in Issue

Year 2026 Volume: 6 Number: 2

DOI

https://doi.org/10.66235/kumj.1888856

IZ

https://izlik.org/JA23RC65UK

Cite

RIS / Bibtex

APA

Özgöz, A. (2026). Integrative in silico analysis suggests miR-152-3p as a potential regulator of DNMT1 in breast cancer, with implications for triple-negative breast cancer. Kastamonu Medical Journal, 6(2), 176-185. https://doi.org/10.66235/kumj.1888856

AMA

1.Özgöz A. Integrative in silico analysis suggests miR-152-3p as a potential regulator of DNMT1 in breast cancer, with implications for triple-negative breast cancer. Kastamonu Medical Journal. 2026;6(2):176-185. doi:10.66235/kumj.1888856

Chicago

Özgöz, Asuman. 2026. “Integrative in Silico Analysis Suggests MiR-152-3p As a Potential Regulator of DNMT1 in Breast Cancer, With Implications for Triple-Negative Breast Cancer”. Kastamonu Medical Journal 6 (2): 176-85. https://doi.org/10.66235/kumj.1888856.

EndNote

Özgöz A (June 1, 2026) Integrative in silico analysis suggests miR-152-3p as a potential regulator of DNMT1 in breast cancer, with implications for triple-negative breast cancer. Kastamonu Medical Journal 6 2 176–185.

IEEE

[1]A. Özgöz, “Integrative in silico analysis suggests miR-152-3p as a potential regulator of DNMT1 in breast cancer, with implications for triple-negative breast cancer”, Kastamonu Medical Journal, vol. 6, no. 2, pp. 176–185, June 2026, doi: 10.66235/kumj.1888856.

ISNAD

Özgöz, Asuman. “Integrative in Silico Analysis Suggests MiR-152-3p As a Potential Regulator of DNMT1 in Breast Cancer, With Implications for Triple-Negative Breast Cancer”. Kastamonu Medical Journal 6/2 (June 1, 2026): 176-185. https://doi.org/10.66235/kumj.1888856.

JAMA

1.Özgöz A. Integrative in silico analysis suggests miR-152-3p as a potential regulator of DNMT1 in breast cancer, with implications for triple-negative breast cancer. Kastamonu Medical Journal. 2026;6:176–185.

MLA

Özgöz, Asuman. “Integrative in Silico Analysis Suggests MiR-152-3p As a Potential Regulator of DNMT1 in Breast Cancer, With Implications for Triple-Negative Breast Cancer”. Kastamonu Medical Journal, vol. 6, no. 2, June 2026, pp. 176-85, doi:10.66235/kumj.1888856.

Vancouver

1.Asuman Özgöz. Integrative in silico analysis suggests miR-152-3p as a potential regulator of DNMT1 in breast cancer, with implications for triple-negative breast cancer. Kastamonu Medical Journal. 2026 Jun. 1;6(2):176-85. doi:10.66235/kumj.1888856